SUSTAIN 6, a cardiovascular outcomes trial, revealed a 26% reduction in major adverse cardiovascular events (MACE) including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke
TL;DR: The GLP-1 receptor agonist landscape in 2026 spans four distinct compounds: semaglutide (selective GLP-1 RA, MW 4113.58 Da, injectable and oral), tirzepatide (dual GLP-1/GIP agonist, MW 4813.45 Da), retatrutide (triple GLP-1/GIP/glucagon agonist, MW ~4500 Da, Phase 3), and orforglipron (non-peptide oral GLP-1 agonist, MW 541.65 Da, FDA-approved April 2026)
This new descriptor differentiates percutaneous discectomy reported with CPT 62287 from the additional work included in the endoscopic discectomy that involves the partial bony removal of lamina, facet and pars interarticularis.
Lemon Bottle is associated with a milder recovery